Stryker Co. (NYSE:SYK) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Stryker Co. (NYSE:SYK) have been given an average recommendation of “Moderate Buy” by the fourteen research firms that are covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $335.27.

SYK has been the topic of a number of analyst reports. Evercore ISI upped their target price on Stryker from $340.00 to $370.00 and gave the company an “outperform” rating in a research note on Thursday. Canaccord Genuity Group raised Stryker from a “hold” rating to a “buy” rating and set a $360.00 target price on the stock in a research note on Wednesday, January 31st. Roth Mkm upped their target price on Stryker from $345.00 to $348.00 and gave the company a “buy” rating in a research note on Wednesday, January 31st. StockNews.com raised Stryker from a “hold” rating to a “buy” rating in a research note on Tuesday, January 23rd. Finally, Citigroup upped their target price on Stryker from $362.00 to $406.00 and gave the company a “buy” rating in a research note on Wednesday.

Insiders Place Their Bets

In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of the company’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the completion of the sale, the chief accounting officer now owns 3,675 shares in the company, valued at $1,317,414. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, Director Ronda E. Stryker sold 201,146 shares of the company’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $342.90, for a total transaction of $68,972,963.40. Following the transaction, the director now directly owns 3,755,128 shares of the company’s stock, valued at $1,287,633,391.20. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CAO William E. Berry, Jr. sold 7,690 shares of the company’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total value of $2,756,711.20. Following the transaction, the chief accounting officer now directly owns 3,675 shares in the company, valued at $1,317,414. The disclosure for this sale can be found here. Insiders sold a total of 212,109 shares of company stock worth $72,845,768 over the last 90 days. Company insiders own 5.90% of the company’s stock.

Hedge Funds Weigh In On Stryker

A number of large investors have recently made changes to their positions in the business. Faithward Advisors LLC increased its position in shares of Stryker by 3.1% in the 4th quarter. Faithward Advisors LLC now owns 973 shares of the medical technology company’s stock valued at $291,000 after acquiring an additional 29 shares during the period. Bremer Bank National Association increased its position in shares of Stryker by 4.0% in the 4th quarter. Bremer Bank National Association now owns 888 shares of the medical technology company’s stock valued at $266,000 after acquiring an additional 34 shares during the period. Simon Quick Advisors LLC increased its position in shares of Stryker by 3.0% in the 4th quarter. Simon Quick Advisors LLC now owns 1,158 shares of the medical technology company’s stock valued at $347,000 after acquiring an additional 34 shares during the period. Consolidated Portfolio Review Corp increased its position in shares of Stryker by 3.6% in the 4th quarter. Consolidated Portfolio Review Corp now owns 983 shares of the medical technology company’s stock valued at $294,000 after acquiring an additional 34 shares during the period. Finally, FourThought Financial Partners LLC increased its position in shares of Stryker by 3.3% in the 4th quarter. FourThought Financial Partners LLC now owns 1,076 shares of the medical technology company’s stock valued at $322,000 after acquiring an additional 34 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Trading Down 1.0 %

Shares of NYSE SYK opened at $347.43 on Friday. The business’s 50 day moving average is $347.58 and its two-hundred day moving average is $307.64. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.58 and a quick ratio of 0.97. Stryker has a 1-year low of $249.98 and a 1-year high of $361.41. The stock has a market capitalization of $132.19 billion, a P/E ratio of 42.70, a PEG ratio of 2.85 and a beta of 0.89.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share for the quarter, topping the consensus estimate of $3.27 by $0.19. Stryker had a return on equity of 22.99% and a net margin of 15.44%. The company had revenue of $5.82 billion for the quarter, compared to analysts’ expectations of $5.60 billion. During the same period in the previous year, the firm posted $3.00 earnings per share. The firm’s revenue for the quarter was up 11.8% on a year-over-year basis. As a group, research analysts expect that Stryker will post 11.86 EPS for the current year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be issued a dividend of $0.80 per share. The ex-dividend date is Wednesday, March 27th. This represents a $3.20 dividend on an annualized basis and a yield of 0.92%. Stryker’s dividend payout ratio is currently 38.79%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.